【摘要】：目的：研究抗病毒治療對慢乙肝相關(guān)原發(fā)性肝癌危險因素的干預(yù)作用,從而為臨床提供相關(guān)數(shù)據(jù)。 方法：收集青島市傳染病醫(yī)院2010年2月至2012年6月住院的乙肝相關(guān)性肝癌患者病例,共計251例,排除其他病毒性肝炎、酒精性肝炎、自身免疫性肝炎等相關(guān)疾病患者病例,將其余232例納入研究。通過統(tǒng)一編制的調(diào)查表記錄相關(guān)數(shù)據(jù)信息。根據(jù)患者于診斷為HCC前有無抗病毒治療史將其分為兩組,抗病毒治療組95例,非抗病毒治療組137例,分析比較兩組間各相關(guān)高危因素的分布差異。 結(jié)果：在抗病毒治療組與非抗病毒治療組患者HBV DNA載量、HBeAg性質(zhì)、HBV感染時間、肝硬化史等分布,差異均有統(tǒng)計學(xué)意義(P0.05),抗病毒組患者的HBV DNA載量明顯較低,其組內(nèi)患者被診斷為HCC前的HBV感染時間、肝硬化史均較長；兩組間慢乙肝家族史、肝癌家族史差異無統(tǒng)計學(xué)意義(P0.05)。 結(jié)論：1.抗病毒治療有利于乙肝相關(guān)性肝癌患者的HBeAg發(fā)生陰轉(zhuǎn)、降低患者體內(nèi)HBV DNA載量。2.抗病毒治療不能降低慢乙肝家族史、肝癌家族史所致HCC發(fā)病的風(fēng)險。3.抗病毒治療可以有效延緩慢乙肝到HCC的進(jìn)展,進(jìn)而或可降低HCC發(fā)病率。
[Abstract]:Objective: to study the intervention effect of antiviral therapy on risk factors of primary liver cancer associated with chronic hepatitis B (CHB), so as to provide relevant data for clinic. Methods: a total of 251 patients with hepatitis B associated liver cancer hospitalized in Qingdao Infectious Diseases Hospital from February 2010 to June 2012 were collected and excluded from other viral hepatitis, alcoholic hepatitis, autoimmune hepatitis and other related diseases. The remaining 232 cases were included in the study. The relevant data and information are recorded through the unified questionnaire. According to the history of antiviral therapy before diagnosis of HCC, the patients were divided into two groups: antiviral treatment group (n = 95) and non-antiviral treatment group (n = 137). The distribution differences of related high risk factors between the two groups were analyzed and compared. Results: there were significant differences in the distribution of HBV DNA load, HBeAg nature, HBV infection time and history of liver sclerosis between antiviral group and non-antiviral treatment group (P 0.05). The HBV DNA load of patients in antiviral group was significantly lower than that in non-antiviral group. The patients in the group were diagnosed with HBV infection before HCC and the history of liver sclerosis was longer. There was no significant difference in the family history of chronic hepatitis B and liver cancer between the two groups (P 0.05). Conclusion: 1. Antiviral therapy is beneficial to the negative conversion of HBeAg and the reduction of HBV DNA load in patients with hepatitis B associated liver cancer. 2. Antiviral therapy can not reduce the risk of HCC caused by family history of chronic hepatitis B and liver cancer. 3. Antiviral therapy can effectively delay the progress of chronic hepatitis B to HCC, and then reduce the incidence of HCC.
【學(xué)位授予單位】：青島大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2014
【分類號】：R512.62;R735.7

【引證文獻(xiàn)】

相關(guān)期刊論文 前1條

1 李戰(zhàn)英;;乙肝相關(guān)性原發(fā)性肝癌預(yù)后因素分析及抗病毒治療的臨床研究[J];臨床合理用藥雜志;2017年16期

相關(guān)博士學(xué)位論文 前1條

1 王紹波;~(18)F-FDG PET/CT早期動態(tài)顯像在肝癌診斷中的臨床應(yīng)用[D];南方醫(yī)科大學(xué);2015年

，

本文編號：2487194